產(chǎn)品名稱：Human IL6 Protein, Recombinant
純度：≥95 % as determined by SDS-PAGE
內(nèi)毒素：< 1.0 EU per μg of the protein as determined by the LAL method
生物活性：/
序列起止：Val30~Met 212
標簽：N-His tag
Uniprot鏈接：P05231
表達系統(tǒng)：293F
種屬：Human
預測 N 端：Met
預測分子量：/
緩沖液：20mM Tris, 250mM imidazole, 500mM NaCl, pH8.0, containing 10% glycerol.
運輸方式：This Protein is shipped as lyophilized powder at ambient temperature. Upon receipt, store it immediately at the temperature recommended.
穩(wěn)定性 & 儲存條件：Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
復溶：Please refer to COA for detailed information
質(zhì)量驗證圖：/
別稱：MGI2-A, MGI2A, HGF, BSF2, HSF, IFNB2, B-Cell Stimulatory Factor-2, Hybridoma/Plasmacytoma Growth Factor, Hepatocyte Stimulating Factor, Cytotoxic T-Cell Differentiation Factor
背景信息：IL-6. Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression (1-5). Mature feline IL-6 is 181 amino acids (aa) in length and shares 56%, 35%, 38%, and 76% aa sequence identity with human, mouse, rat, and canine IL-6, respectively IL-6 (6, 7). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization (8). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (9). Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage (5). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha (5). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes (2, 5). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor (5, 10). IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease (1-5). When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis (1, 2, 5). IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise (2). In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells (1, 11).
全稱：Interleukin-6 (IL6)